Geode Capital Management LLC Increases Stock Holdings in Immunome, Inc. (NASDAQ:IMNM)

Geode Capital Management LLC increased its stake in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 13.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,207,455 shares of the company's stock after buying an additional 144,557 shares during the quarter. Geode Capital Management LLC owned 2.01% of Immunome worth $17,657,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Marshall Wace LLP lifted its holdings in Immunome by 228.5% during the second quarter. Marshall Wace LLP now owns 1,713,325 shares of the company's stock worth $20,731,000 after acquiring an additional 1,191,774 shares during the period. Janus Henderson Group PLC raised its stake in shares of Immunome by 10.3% during the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company's stock worth $50,971,000 after purchasing an additional 324,614 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Immunome by 217.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company's stock worth $6,469,000 after purchasing an additional 302,916 shares during the period. Victory Capital Management Inc. grew its position in Immunome by 48.1% during the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company's stock valued at $10,684,000 after buying an additional 237,497 shares during the period. Finally, AXA S.A. purchased a new stake in Immunome during the second quarter worth about $2,174,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on IMNM shares. Wedbush reaffirmed an "outperform" rating and issued a $33.00 price target on shares of Immunome in a report on Friday, October 25th. Stephens initiated coverage on Immunome in a research note on Friday, November 8th. They issued an "overweight" rating and a $30.00 target price on the stock. Finally, Piper Sandler cut their price target on Immunome from $23.00 to $21.00 and set an "overweight" rating for the company in a research note on Thursday, November 14th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $28.83.

Immunome Trading Down 2.5 %

Shares of IMNM traded down $0.26 during midday trading on Monday, reaching $10.28. The stock had a trading volume of 464,055 shares, compared to its average volume of 787,956. The company has a market capitalization of $641.68 million, a price-to-earnings ratio of -1.27 and a beta of 1.83. The company's 50-day moving average is $12.01 and its 200 day moving average is $13.16. Immunome, Inc. has a 12-month low of $8.97 and a 12-month high of $30.96.

Insiders Place Their Bets

In related news, CTO Philip Tsai acquired 21,000 shares of the stock in a transaction on Thursday, November 21st. The stock was purchased at an average price of $9.43 per share, for a total transaction of $198,030.00. Following the completion of the transaction, the chief technology officer now owns 21,000 shares of the company's stock, valued at $198,030. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Clay B. Siegall bought 66,057 shares of the business's stock in a transaction dated Thursday, November 21st. The stock was purchased at an average price of $9.54 per share, for a total transaction of $630,183.78. Following the acquisition, the chief executive officer now directly owns 485,693 shares of the company's stock, valued at approximately $4,633,511.22. The trade was a 15.74 % increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 102,862 shares of company stock valued at $978,045 over the last quarter. 8.60% of the stock is owned by corporate insiders.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.